In our case LMS1, although we could not detect any gene mutations in 3 FFPE tumor specimens, we detected non-synonymous somatic mutations in the KRAS and receptor tyrosine-protein kinase erbB-2 (ERBB2) genes, both of which are known to be important actionable genes, in the analysis of the patient’s ctDNA. Here, ERBB2 is linked to neoplasm.